These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. de Visser M; Verwijnen SM; de Jong M Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684 [TBL] [Abstract][Full Text] [Related]
5. Peptide-based radiopharmaceuticals for targeted tumor therapy. Dong C; Liu Z; Wang F Curr Med Chem; 2014; 21(1):139-52. PubMed ID: 23992337 [TBL] [Abstract][Full Text] [Related]
6. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488 [TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours. Alsadik S; Yusuf S; Al-Nahhas A Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538 [TBL] [Abstract][Full Text] [Related]
9. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors. Giovacchini G; Nicolas G; Forrer F Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758 [TBL] [Abstract][Full Text] [Related]
10. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]
11. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723 [TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203 [TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical studies of peptide receptor radionuclide therapy. Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630 [TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. Strosberg J; Leeuwenkamp O; Siddiqui MK Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096 [TBL] [Abstract][Full Text] [Related]
15. Design, preparation and biological evaluation of a Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215 [TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925 [TBL] [Abstract][Full Text] [Related]
17. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115 [TBL] [Abstract][Full Text] [Related]
18. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Feijtel D; Reuvers TGA; van Tuyll-van Serooskerken C; de Ridder CMA; Stuurman DC; de Blois E; Verkaik NS; de Bruijn P; Koolen SLW; de Jong M; Nonnekens J Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765883 [TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. Hirmas N; Jadaan R; Al-Ibraheem A Nucl Med Mol Imaging; 2018 Jun; 52(3):190-199. PubMed ID: 29942397 [TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Pfeifer AK; Gregersen T; Grønbæk H; Hansen CP; Müller-Brand J; Herskind Bruun K; Krogh K; Kjær A; Knigge U Neuroendocrinology; 2011; 93(3):189-96. PubMed ID: 21335949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]